Financials in USD. Standardized financial statements.
A compact view of how Evaxion Biotech A/S turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $7.53M | $3.34M | $73,000 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +125.1% | +4480.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $80,984 | $73,928 |
| Gross Profit? | $7.53M | $3.34M | $73,000 | $0 | $0 | $0 | -$80,984 | -$73,928 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $16.76M | $18.08M | $22.27M | $25.26M | $25.83M | $16.57M | $11.28M | $5.63M |
| Operating Income? | -$9.23M | -$14.73M | -$22.20M | -$25.26M | -$25.83M | -$16.57M | -$11.36M | -$5.63M |
| EBITDA? | -$7.12M | -$9.79M | -$21.40M | -$22.57M | -$24.21M | -$16.46M | -$11.90M | -$6.18M |
| Income Before Tax | -$8.62M | -$11.36M | -$22.91M | -$23.94M | -$24.71M | -$16.57M | -$12.02M | -$6.27M |
| Income Tax Expense | -$908,000 | -$788,000 | -$790,000 | -$772,000 | -$178,000 | -$1.56M | -$824,837 | -$735,000 |
| Net Income? | -$7.71M | -$10.57M | -$22.13M | -$23.17M | -$24.53M | -$15.02M | -$11.19M | -$5.54M |
| EPS? | $-1.21 | $-9.80 | $-32.40 | $-39.20 | $-50.40 | $-37.00 | $-27.60 | $-11.52 |
| Diluted EPS? | $-1.21 | $-9.80 | $-32.40 | $-39.20 | $-50.40 | $-37.00 | $-27.60 | $-11.52 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality